These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33871787)

  • 61. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
    George P; Brown A; Weinkove R
    Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864
    [No Abstract]   [Full Text] [Related]  

  • 62. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Schnitzler syndrome is a diagnostic challenge].
    Duhn PH; Thomsen SF; Nordin H
    Ugeskr Laeger; 2015 Jul; 177(30):. PubMed ID: 26240044
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Anakinra and Schnitzler's syndrome].
    Saiz E; Gálvez J; Mora A; Contreras L
    Med Clin (Barc); 2008 Mar; 130(9):358-9. PubMed ID: 18373918
    [No Abstract]   [Full Text] [Related]  

  • 65. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 66. Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
    Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668876
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Variable Responses to Tocilizumab in Four Patients with Schnitzler Syndrome.
    Claus J; Vanderschueren S
    J Clin Immunol; 2019 May; 39(4):370-372. PubMed ID: 31111419
    [No Abstract]   [Full Text] [Related]  

  • 68. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
    Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Schnitzler syndrome: treatment failure to rituximab but response to anakinra.
    Eiling E; Möller M; Kreiselmaier I; Brasch J; Schwarz T
    J Am Acad Dermatol; 2007 Aug; 57(2):361-4. PubMed ID: 17467852
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Canakinumab in Schnitzler syndrome.
    Vanderschueren S; Knockaert D
    Semin Arthritis Rheum; 2013 Feb; 42(4):413-6. PubMed ID: 22901459
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Evaluation of 2-year treatment of Schnitzler syndrome (urticarial exanthema, monoclonal IgM gammopathy and osteolytic-osteosclerotic skeletal changes) using Anakinra (Kineret)].
    Adam Z; Krejcí M; Pour L; Hájek R
    Vnitr Lek; 2009 Dec; 55(12):1196-7. PubMed ID: 20070037
    [No Abstract]   [Full Text] [Related]  

  • 72. Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
    Pulido-Pérez A; Bergón-Sendín M; Mateos-Mayo A; Parra-Blanco V; Suárez-Fernández R; Carretero-López F
    Ann Hematol; 2021 Dec; 100(12):3065-3066. PubMed ID: 33026479
    [No Abstract]   [Full Text] [Related]  

  • 73. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 74. [Schnitzler syndrome--unknown, rare but treatable].
    Lazarevic V; Markuszewska A; Stenberg B; Häggroth J
    Lakartidningen; 2008 Nov 12-18; 105(46):3348-51. PubMed ID: 19062627
    [No Abstract]   [Full Text] [Related]  

  • 75. Occurrence of Rheumatoid Arthritis in a Patient Treated with Anakinra for Schnitzler Syndrome: A Case Report.
    Margerin F; Gottenberg JE; Lipsker D
    J Rheumatol; 2016 Jul; 43(7):1447. PubMed ID: 27371651
    [No Abstract]   [Full Text] [Related]  

  • 76. A case of inflammatory myopathy in graft vs host disease - A potential role for ibrutinib.
    Wilkinson M; Yeung D; Limaye V
    Neuromuscul Disord; 2021 Sep; 31(9):865-869. PubMed ID: 34334272
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
    Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 79. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
    Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
    Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
    [No Abstract]   [Full Text] [Related]  

  • 80. The Schnitzler syndrome: chronic urticaria in disguise: a single-centre report of 11 cases and a critical reappraisal of the literature.
    Vanderschueren S; van der Veen A
    Clin Exp Rheumatol; 2017; 35(1):69-73. PubMed ID: 27606610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.